
Role of APCC in managing Haemophilia with Inhibitors
Tuesday, December 16th 2025 - 1:30 PM (IST)
3 days to go
243 doctors attending
Tuesday, December 16th 2025 - 1:30 PM (IST)
About this session
Managing haemophilia with inhibitors remains one of the most complex challenges in bleeding disorder care. Standard factor replacement therapies often become ineffective, leading to increased bleeding risk and reduced quality of life. This session explores the role of Activated Prothrombin Complex Concentrates (APCC) as a critical bypassing agent in overcoming these treatment hurdles. Join us to understand the indications, dosing strategies, and clinical considerations involved in APCC use, and how it can be integrated effectively into the management of patients with haemophilia and inhibitors.
Faculty
Key details
Registration
Free
Duration
60 min
Replay
Yes
Certificate
No
Language
English
Supported by

Explore other sessions
Disclaimer
The information provided in this video is aimed at increasing awareness on Hemophilia for Registered Healthcare Practitioner / Registered Medical Practitioner only and it is not meant for promotion or recommendation of any specific product. This information and video should not be used or shared or distributed to any other person / party and should be strictly used by the intended per se for the intended purposes only. Registered Healthcare Practitioner / Registered Medical Practitioner shall apply their independent medical judgement for diagnosing or assessing or treating any patient. Takeda makes no representation or warranty concerning the information /content provided in this video and assumes no responsibility for the accuracy of the information or content or of the opinion furnished or any outcome based on the application of such information. This video contains copyright protected information, content; the use of which is limited by law and this video cannot be reproduced, replicated, used, or modified by any person for their own use or further distribution. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited.

